Dengvaxia is recommended for individuals aged 9-45 years who live in endemic areas and have had a prior dengue infection. This is because studies have shown that the vaccine's efficacy is higher in those who have been previously exposed to dengue. Furthermore, individuals with no prior dengue infection may be at risk for severe dengue if they receive the vaccine and then contract dengue for the first time.
